Literature DB >> 24097221

Influence of renal dysfunction on clinical outcomes in patients with congestive heart failure complicating acute myocardial infarction.

Chang Seong Kim1, Min Jee Kim, Yong Un Kang, Joon Seok Choi, Eun Hui Bae, Seong Kwon Ma, Young-Keun Ahn, Myung Ho Jeong, Young Jo Kim, Myeong Chan Cho, Chong Jin Kim, Soo Wan Kim.   

Abstract

The clinical course and medical treatment of patients with congestive heart failure (CHF) complicating acute myocardial infarction (AMI) are not well established, especially in patients with concomitant renal dysfunction. We performed a retrospective analysis of the prospective Korean Acute Myocardial Infarction Registry to assess the medical treatments and clinical outcomes of patients with CHF (Killip classes II or III) complicated by AMI, in the presence or absence of renal dysfunction. Of 13,498 patients with AMI, 2769 (20.5%) had CHF on admission. Compared to CHF patients with preserved renal function, in-hospital mortality and major adverse cardiac events were increased both at 1 month and at 1 year after discharge in patients with renal dysfunction (1154; 41.7%). Postdischarge use of aspirin, betablockers, calcium channel blockers, angiotensin-converting enzyme inhibitors, or angiotensin II receptor blockers and statins significantly reduced the 1-year mortality rate for CHF patients with renal dysfunction; such reduction was not observed for those without renal dysfunction, except in the case of aspirin. Patients with CHF complicating AMI, which is accompanied by renal dysfunction, are at higher risk for adverse cardiovascular outcomes than patients without renal dysfunction. However, they receive fewer medications proven to reduce mortality rates.

Entities:  

Mesh:

Year:  2013        PMID: 24097221     DOI: 10.1536/ihj.54.304

Source DB:  PubMed          Journal:  Int Heart J        ISSN: 1349-2365            Impact factor:   1.862


  4 in total

Review 1.  The scientific achievements of the decades in Korean Acute Myocardial Infarction Registry.

Authors:  Hyun Kuk Kim; Myung Ho Jeong; Seung Hun Lee; Doo Sun Sim; Young Joon Hong; Youngkeun Ahn; Chong Jin Kim; Myeong Chan Cho; Young Jo Kim
Journal:  Korean J Intern Med       Date:  2014-10-31       Impact factor: 2.884

2.  Efficacy of Zofenopril Compared With Placebo and Other Angiotensin-converting Enzyme Inhibitors in Patients With Acute Myocardial Infarction and Previous Cardiovascular Risk Factors: A Pooled Individual Data Analysis of 4 Randomized, Double-blind, Controlled, Prospective Studies.

Authors:  Claudio Borghi; Stefano Omboni; Giorgio Reggiardo; Stefano Bacchelli; Daniela Degli Esposti; Ettore Ambrosioni
Journal:  J Cardiovasc Pharmacol       Date:  2017-01       Impact factor: 3.105

3.  Combination therapy with beraprost sodium and aspirin for acute ischemic stroke: a single-center retrospective study.

Authors:  Xiao-Pu Chen; Dun-Can Wei; Qian Zhang; Si-Qia Chen; Wen-Zhen He
Journal:  J Int Med Res       Date:  2019-05-30       Impact factor: 1.671

4.  In-hospital outcome of primary PCI for patients with acute myocardial infarction and prior coronary artery bypass grafting.

Authors:  Yu Liu; Le-Feng Wang; Xin-Chun Yang; Pi-Xiong Su; Kui-Bao Li; Hong-Shi Wang; Mu-Lei Chen; Li Xu; Jiu-Chang Zhong
Journal:  J Thorac Dis       Date:  2021-03       Impact factor: 2.895

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.